Loading stock data…
DYN
$17.92+1.11 (+6.60%)
After Hours$18.00+0.08 (+0.45%)· Last close Jun 9
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Dyne Therapeutics, Inc. in the Healthcare sector is trading at $17.92. Wall Street consensus targets $38.25 (16 analysts), implying a +113.4% move over the next 12 months. The stock is currently 28% below its 52-week high of $25.00, remaining 2.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +113.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$17.92
Potential Downside
0%
Whystock Fair Value$17.92
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target$38.25+113.4%
Range$17.00 – $50.00
Fundamentals
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, includi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-52.22%
Volume
Today's trading volume
1.67M
Recent News
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 26, Dyne Therapeutics Inc. (NASDAQ:DYN) reached a major regulatory milestone by submitting its official Biologics License Application to the FDA for its new Duchenne muscular dystrophy treatment, z-rostudirsen. The company is seeking a Priority Review […]
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone
Dyne Therapeutics (DYN) has fully enrolled the registrational expansion cohort of its Phase 1/2 ACHIEVE trial for z-basivarsen in myotonic dystrophy type 1, a key step toward potential U.S. Accelerated Approval. See our latest analysis for Dyne Therapeutics. The latest clinical milestones appear to be feeding into improving sentiment, with Dyne’s share price at US$18.41 and a 90 day share price return of 23.89%. The 1 year total shareholder return of 31.59% and 3 year total shareholder return...
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
DYN shares jump after the company files a BLA with the FDA for z-rostudirsen in Duchenne muscular dystrophy.